Anders H Rosengren

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 11

Top Topics

Cardiovascular Risk Factors

Glycemic Control

Top Venues

Nature metabolism

NPJ digital medicine

Diabetes therapy : research, treatment and education of diabetes and related disorders

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)
Chinmay Dwibedi, Ola Ekström, Jasmine Brandt, Martin Adiels, Stefan Franzén, Birgitta Abrahamsson, Anders H Rosengren
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature metabolism 6 (1) (2024)
Vishal A Salunkhe, Neha Sinha, Emma Ahlqvist, Rashmi B Prasad, Svetlana Johansson, Birgitta Abrahamsson, Anders H Rosengren
Digital lifestyle treatment improves long-term metabolic control in type 2 diabetes with different effects in pathophysiological and genetic subgroups. NPJ digital medicine 6 (1) (2023)
Chinmay Dwibedi, Birgitta Abrahamsson, Anders H Rosengren
Effect of Digital Lifestyle Management on Metabolic Control and Quality of Life in Patients with Well-Controlled Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders 13 (3) (2022)
Chinmay Dwibedi, Emelia Mellergård, Amaru Cuba Gyllensten, Kristoffer Nilsson, Annika S Axelsson, Malin Bäckman, Magnus Sahlgren, Stephen H Friend, Sofie Persson, Stefan Franzén, Birgitta Abrahamsson, Katarina Steen Carlsson, Anders H Rosengren
Effect of self-managed lifestyle treatment on glycemic control in patients with type 2 diabetes. NPJ digital medicine 5 (1) (2022)
Annika S Axelsson, Emily Tubbs, Brig Mecham, Shaji Chacko, Hannah A Nenonen, Yunzhao Tang, Jed W Fahey, Jonathan M J Derry, Claes B Wollheim, Nils Wierup, Morey W Haymond, Stephen H Friend, Hindrik Mulder, Anders H Rosengren
Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. Science translational medicine 9 (394) (2018)